Iaccarino Leonardo, Burnham Samantha C, Tunali Ilke, Wang Jian, Navitsky Michael, Arora Anupa K, Pontecorvo Michael J
Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA; Eli Lilly Italia S.p.A., Sesto Fiorentino FI 50019, Italy.
Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA.
Neuroimage Clin. 2025 Mar 10;46:103765. doi: 10.1016/j.nicl.2025.103765.
The density of brain amyloid-beta neuritic plaque accumulation, a marker of Alzheimer's disease (AD), can be visualized and quantified using amyloid-positron emission tomography (PET). Amyloid-PET data can be obtained using different tracers and methodologies; therefore, comparison across studies can be difficult. The introduction of Centiloids in 2015 allowed for the transformation of amyloid-PET quantitative data to a common scale, enhancing comparability across studies and potentially enabling pooled analysis. Since then, Centiloid values have been used increasingly in research and clinical trials for multiple purposes, being tested and validated with a variety of clinical, biomarker and pathological standards of truth. In clinical trials, Centiloid values have been used for patient selection, to confirm the presence of AD pathology, as well as for treatment monitoring, especially in trials of disease-modifying treatments such as amyloid-targeting therapies. Building on their widespread adoption, Centiloid values are increasingly being integrated into commercially available software solutions for quantifying amyloid-PET, paving the way for real-world applications at the community level. This article addresses frequently asked questions about Centiloid definition, implementation, interpretation, and caveats, and also summarizes the available literature on published thresholds, ultimately supporting wider access and informed use of Centiloid values in Alzheimer's disease research.
脑淀粉样β神经炎性斑块积聚是阿尔茨海默病（AD）的一个标志物，其密度可通过淀粉样正电子发射断层扫描（PET）进行可视化和量化。淀粉样PET数据可使用不同的示踪剂和方法获得；因此，不同研究之间的比较可能会很困难。2015年引入的百分位数（Centiloids）使得淀粉样PET定量数据能够转换为一个通用量表，增强了不同研究之间的可比性，并有可能实现汇总分析。从那时起，百分位数在研究和临床试验中的使用越来越广泛，用于多种目的，并通过各种临床、生物标志物和病理学真值标准进行了测试和验证。在临床试验中，百分位数已用于患者选择、确认AD病理学的存在以及治疗监测，特别是在针对淀粉样蛋白靶向治疗等疾病修饰治疗的试验中。基于其广泛采用，百分位数越来越多地被整合到用于量化淀粉样PET的商业软件解决方案中，为社区层面的实际应用铺平了道路。本文解答了关于百分位数定义、实施、解释和注意事项的常见问题，并总结了关于已发表阈值的现有文献，最终支持在阿尔茨海默病研究中更广泛地获取和明智地使用百分位数。
